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Metabolism of 25-OH-vitamin D3 by peritoneal macrophages from
CAPD patients. The active metabolite of vitamin D, I ,25-dihydroxycho-
lecalciferol (1,25(OH)2D3), is produced mainly by the kidney, but there
is evidence for extrareñal production in certain circumstances. We
studied whether peritoneal macrophages (PM) from CAPD patients
were capable of metabolizing 25-OH-D3 to 1 ,25(OH)2D3. We found that
PM were able to metabolize 25-OH-D3 in vitro; the main product
following 16 hours of incubation was 19-nor, 10-oxo, 25-OH-D3 with
smaller amounts of l,25(OH)2D3. However, after shorter incubations of
three and five hours a larger portion of I ,25(OH)2D3 was produced. The
metabolism of 25-OH-D3 was greatly enhanced in PM harvested during
episodes of peritonitis. This property was specific for PM of CAPD
patients, and was not found in PM from normal subjects. However,
incubation of control PM with peritoneal effluent from CAPD patients
resulted in induction of the ability of these cells to metabolize 25-OH-
D3. This induction was enhanced by preincubation with peritoneal
effluent from CAPD patients suffering from peritonitis. Prostaglandin E2
was found to be involved in this synthesis: addition of POE2 to normal
PM induced metabolism of 25-OH-D3, and incubation of PM from
CAPD patients with indomethacin decreased the metabolism of 25-OH-
D3. The vitamin D metabolites produced by PM from CAPD patients
could have a role in immunological resistance to peritoneal infections.
It is generally accepted that the active metabolite of vitamin
D, 1,25-dihydroxycholecalciferol (l,25(OH)2D3) is produced by
the kidney [1]. Recent studies, however, have provided evi-
dence for extrarenal production of 1 ,25(OH)2D3, such as in the
endometrium and placenta of pregnant women [2], human chon-
drocytes and bone cells [3]. Adams et al [41 demonstrated that
alveolar macrophages obtained from sarcoidosis patients are ca-
pable of converting 25-hydroxyvitamin D into 1 ,25(OH)2D3, and
the extrarenal production of I ,25(OH)2D3 was confirmed by the
high levels of this metabolite found in anephric patients with
sarcoidosis [51.
In recent years, the technique of continuous ambulatory
peritoneal dialysis (CAPD) has become increasingly used to
treat patients suffering from end-stage renal disease. Since renal
synthesis of l,25(OH)2D3 is reduced in these patients, we
thought it of interest to investigate whether peritoneal macro-
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phages from CAPD patients are capable of the synthesis of this
hormone.
Methods
Harvesting of peritoneal macrophages
Peritoneal macrophages (PM) were obtained from 13 uremic
patients who had been receiving CAPD for at least one year,
and had been free of peritonitis for at least two months prior to
the study. PM were also collected from a group of 9 CAPD
patients suffering from acute bacterial peritonitis.
CAPD was performed by the usual technique by means of
an indwelling Tenckhoff catheter, using three eight-hour ex-
changes, each of 2 1 "Dianeal" (Travenol©) daily, containing
(mmol/liter): Na 141, Ca 3.5, Mg 1.5, Cl 101, lactate 45 and
glucose 1.5%.
Normal PM were obtained from patients undergoing elective
cholecystectomy with no signs of active cholecystitis by means
of peritoneal lavage with Dianeal solution.
PM were centrifuged at 150 g for 20 minutes at 4°C and
resuspended in RPMI 1640 medium containing 10% fetal calf
serum (FCS), 2 mivi L-glutamine, 100 U/ml penicillin 100 tg/ml
streptomycin and 12.5 U/ml nystatin (Biological Industries, Bet
Haemek, Israel). Cells were plated onto a plastic petri dish and
incubated for one hOur at 37°C in a humidified atmosphere of
5% CO2 in air, in order to render them adherent. Non-adherent
cells were removed by discarding the medium and replacing it
with fresh medium. This procedure was repeated after 16 hours
of incubation under the above conditions. The adherent cells
were released by placing the dish on ice for 30 minutes. The
freed cells were resuspended in FCS-free RPMI 1640 medium
and counted in a hemocytometer. Viability was determined by
trypan blue exclusion, and was found to be greater than 99%.
Phagocytic activity was determined by incubation of 106 PM/mI
with 5 x 106 Candida albicans. The latter were preopsonized
with 10% human serum. After a 60 minute incubation at 37°C,
the cell suspension was centrifuged at 3000 rpm for five min-
utes. A Wright-Giemsa preparation was prepared from the cell
pellet, and the number of PM cells that phagocytose at least one
Candida was counted under the light microscope [61. Since
more than 99% of the cells manifested phagocytic activity, and
were positive by nonspecific esterase staining [7], it follows that
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almost all of the cells isolated by this technique were macro-
phages.
Concentration of cells was adjusted to l06/ml with FCS-free
medium. One ml of cell suspension was transferred into each of
a series of 35 mm diameter plastic petri dishes (Sterilin).
Metabolism experiments
Cells (106/ml) were generally incubated for 16 hours (for 3 and
5 hr in the short incubations) at 37°C in 5% CO2 in air, in the
presence of 200 pmol 25-OH-D3, including 5 x i05 DPM [3H]
25-OH-D3 as a tracer. These incubations were performed with
the PM obtained from CAPD patients and controls in parallel.
The possibility that humoral factors present in the peritoneal
effluent from CAPD patients may be implicated in the metabo-
lism of 25-OH-D3 was studied by incubating PM from control
subjects with undiluted peritoneál effluent. Isolated PM (5 x 106
cells) obtained from non-iiremic subjects were incubated over-
night with 20 ml of: (a) fresh peritoneal dialysis fluid; (b)
cell-free peritoneal effluent obtained from uninfected CAPD
patients; (c) cell-free peritoneal effluent obtained from CAPD
patients with active peritonitis; and (d) RPMI medium contain-
ing PGE2 (3 pmollml), prior to the incubation with [3H] 25-OH-
D3.
Similarly, PM of CAPD patients were incubated with 5
nmol/ml indoniethacin [24] prior to the incubation with [3H]
25-OH-D3,
In a further group of experiments, the possible role of uremic
toxins in the metabolism of 25-OH-D3 by PM was studied by
obtaining the PM from the first exchange of the first dialysis of
chronic ureniic patients. These patients were dialyzed using a
single-use stylet peritoneal catheter (Baxter). The PM were
incubated with [3H] 25-OH-D3 as described above.
The possibility of conversion of 1 ,25(OH)2D3 into 19-nor, 10-
oxo-25-OH-D3 was studied by incubating PM with 200 pmol
1 ,25(OH)2D3, including [3HJ I ,25-OH-D3 in the same conditions
as described abOve for the 25-OH-D1 incubations.
Extraction and determination of metabolites
At the end of the incubation with [3H] 25-OH-D3, (200 pmol,
including,5 x lO DPM) the plates were placed on ice for 30
minutes to release the adherent macrophages. Plates were
scraped with rubber policemen and washed three times with
saline, and both medium and cells were transferred into extrac-
tion vials (3.36 0.33 x i0 DPM were recovered, giving a yield
of 67.1%). The medium and cells were extracted with 5 ml of
cyclohexane : ethylacetate (1: 1 vollvol). This lipid extraction was
repeated five times, after which the extracts were combined, dried
under a nitrogen stream, redissolved in a hexane:isopropanol
(9:1) mixture (3.32 0.34 x i0 DPM were recovered, yield
66.4%). This extract was subjected to high performance liquid
chromatography (LKB-250 HPLC), using the above solvent sys-
tem and a silicic acid column (TSK, Si-l50, 5 micron, 4.6 X 250
mm, LKB). The flow rate was 1.6 mI/mm. Fractions of 0.8 ml
were collected, dried, redissolved in 3 ml scintillation fluid (Insta-
Gel II, Packard) and radioactivity counted. Identification of the
vitamin D metabolite peaks was carried out by parallel chroma-
tography of vitamin D metabolite standards under the same
conditions. To identify the prodUct, the [3HJ 1 ,25(OH)2D3-like PM
metabölite peaks of a few chromatographs were pooled. Unla-
beled vitamin D metabolites were added, and the mixture was
rechromatographed on HPLC using the silicic acid column and
dichloromethane : methanol (97.5:2.5). Fractions were followed
spectrophotometrically (absorbance at 254 nm or 290 nm), and by
simultaneous counting of radioactivity. Similar separations were
carried out on reverse phase HPLC (TSK ODS-120T, 5 micron,
4.6 x 250 mm column, LKB) using methanol: water (85: 15) as
solvent.
Quantitative determinations
The amounts of the vitamin D product produced by the PM
were calculated as the percentage of the pooled counts of the
1 ,25(OHbD3-like peak (Fig. 1 C), out of the combined counts of
the whole HPLC profile (3.01 0.35 x l0 DPM were recov-
ered, yield 60.3%). Actual amounts (pmol) were calculated from
this value and the substrate concentration (200 pmol), and
expressed as mean SE.
Vitamin D metabolite standards
Standards of vitamin D metabolites were provided by Hoff-
man-La Roche, Basel. The standard 19-nor, l0-oxo,25-OH-D3
was the gift of Professor F. Yamada, Tokyo University. [3H]
25-OH-D3 (176 Ci/mmol, Amersham), and [3H] I ,25(OH)2D3
(180 Ci/mmol, Amersham), were dissolved in ethanol, and
freshly diluted in the medium before each experiment. The
ethanol concentration after dilution did not exceed 0.1%. Prior
to the incubation, the degree of purity of the [3H1 25-OH-D1
substrate was tested on HPLC (Fig. 1B).
Results
Human PM obtained from uremic patients treated with
CAPD produced small amounts of vitamin D metabolites that
migrated on HPLC in the same position asthe l,25(OH)2D3
standard (Fig. 1). Since the [3H] 25-OI1-D3 substrate was found
to be pure, without any accompanying radiolabeled compounds
(Fig. lB), it is clear that the metabolites shown in Figure 1C
were produced by the PM during the incubation. As shown in
Figure 2, the cumulative peak of the l,25(OH)2D3-like product
was found to be 9.2 0.8 pmol/l06 cells in 13 patients. In
contrast, the PM obtained from five normal subjects synthe-
sized very small amounts of this product (0.8 0.3 pmolllO6
cells); The synthesis of this product was found to be signifi-
cantly enhanced in nine patients with peritonitis (Fig. 2, P <
0.006).
Preincubation of PM obtained from normal subjects in a
cell free undiluted supernat'int of an overnight peritoneal ef
fluent resultedin stimulation of the macrophages to produce the
1,25(OH)2D3-like product (Fig. 3; P < 0.001). On the other
hand, incubation of normal PM with fresh peritoneal dialysis
solution did nUt result in any enhancement of the 1 ,25(OH)2D3-
like product (Fiil. 3). The effect of peritoneal effluent on normal
PM was mimicked by preincubation with 3 pmoL'ml PGE2 (Fig.
3; normal vs. PGE2, P < 0.002). This concentration was chosen
because in a previous series of experiments, we found that PM
of CAPD patients incubated for 24 hours secreted POE2 at a
Concentration of approximately 3 pmol/ml in the medium [24].
Thus, in this experiment we used similar PGE2 levels.
The involvement of endogenous prostaglandins in the metab-
olism of 25-OH-D3 in PM of CAPD patients was studied by
incubation of PM from CAPD with indomethacin. Figure 4
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Fig. 3. The amount of 1 ,25(OH)2D3-like metabolite produced by mac-
rophages from: (a) normal subjects; (b) macrophages from normal
subjects incubated with fresh dialysis solution; (c) macrophages from
normal subjects incubated with CAPD peritoneal effluent; (d) macro-
phages from normal subjects incubated with dialysis effluent from a
CAPD patient with active peritonitis; (e) macrophages from normal
subjects incubated with PGE2 (3 pmol/ml). Results are expressed as
mean SE. The number of subjects is given in parentheses.
rerun on several different HPLC systems. Rechromatography
on a Zorbax-Sil column, using dichioromethane : methanol
(97.5:2.5) revealed only traces of l,25(OH)2D3, and the major-
ity of the metabolites consisted of two fractions, clearly sepa-
rable from 1 ,25(OH)2D3. The major fraction co-migrated with
19-nor,lO-oxo, 25-OH-D3 (Fig. 5). Reverse phase HPLC, (TSK
ODS-120T column), using methanol: water (85: 15) as solvent,
revealed co-migration of the major fraction of the 1 ,25(OH)2D3-
like metabolite with 19-nor, lO-oxo, 25-OH-D3, while a minor
fraction co-migrated with 1 ,25(OH)2D3 (Fig. 6).
It could be suggested that the main metabolite formed is
indeed I ,25(OH)2D3, but that this is further oxidized to 19-
nor, l0-oxo-25-OH-D3 by PM. This possibility was investigated
by incubating PM with 200 pmol of 25-OH-D3 for various
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Fig. 2. The amount of I ,25(OH)2D3-like metabolite produced by mac-
rophages from normal subjects, CAPD patients, and CAPD patients
during an episode of peritonitis. Results are expressed as mean SE.
The number of subjects is given in parentheses.
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Fig. 1. HPLC of vitamin D3 metabolites on TSK Si-ISO, 5 ji, 4.6 x 250
mm column, eluted at 1.6 mi/mm with 10% isopropanol in hexane. A.
Elution pattern of radioactivity of [3H] 25-OH-D3, [3H1 24,25(OH)2-D3
and [3H] I ,25(OH)2D3 standards. B. Elution patterns of radioactivity of
the [3H] 25-OH-D3 substrate, C. Elution pattern of radioactivity of
extracted PM and medium following incubation for 16 hours in the
presence of 200 pmol PHI 25-OH-D3.
shows that indomethacin caused a significant reduction in the
production of the I ,25(OH)2D3-like metabolite (P = 0.026).
The PM from the first dialysis of chronic uremic patients were
studied. Since these patients were suffering from end-stage
renal disease and had not been previously dialyzed, they would
be expected to have high circulating levels of "uremic toxins".
We found that the PM of these patients showed no metabolism
whatsoever of 25-OH-D3.
To characterize the 1 ,25(OH)2D3-like peak, this fraction was
1 ,25(OH)2D
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1 9-nor-10-oxo-25(OH)D3
incubation periods. While the 16 hour incubation revealed only
6.3% of l,25(OH)2D3 and the rest was found to be 19-nor,10-
oxo-25-OH-D3, shorter incubations of three and five hours,
although yielding smaller amounts of vitamin D products,
revealed a higher percentage of 1 ,25(OH)2D3 (38.3% and 36.1%,
respectively). Moreover, following an overnight incubation of
l,25(OH)2D3 (200 pmol) with PM of CAPD patients (106 cells),
94% of the 1,25(OH)2D3 was converted to 19-nor,l0-oxo-25-
OH-D3 (Fig. 7).
Discussion
In the present study, we have demonstrated that the perito-
neal macrophages from CAPD patients metabolize 25-OH-D3 to
other metabolites, in vitro. Following a long incubation period
of 16 hours, mainly 19-nor,10-oxo, 25-OH-D3 was obtained.
However, after short incubation periods of three and five hours,
a relatively higher amount of 1,25(OH)2D3 was produced. Such
a metabolism of 25-OH-D3 was barely detectable in PM of
nonuremic controls, and was greatly enhanced in CAPD pa-
tients during an episode of acute peritonitis. Our findings are
generally in agreement with those of Hayes et al, who found
metabolism of 25-OH-D3 by PM of CAPD patients who had
undergone attacks of peritonitis in the past, whereas CAPD
patients without previous episodes of peritonitis did not show
this phenomenon [8]. All of our patients had had previous
attacks of peritonitis, and we also found that during an episode
of peritonitis the metabolism of vitamin D by macrophages was
increased.
In our original HPLC study, using the solvent cyclohexane-
isopropanol (9: 1), the main metabolite produced comigrated
with 1,25(OH)2D3, both after long and short incubation periods.
Rechromatography of this peak, with two different separation
systems, including reverse phase HPLC, showed that after the
long incubation, only a small portion of the product was
l,25(OH)2D3, and the majority was 19-nor,10-oxo, 25-OH-D3.
However, short incubation revealed relatively higher amounts
of 1,25(OH)2D3. Hayes et al found that the main metabolite
formed was 1,25(OH)2D3, although some production of 19-
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nor,10-oxo-25-OH-D1 was also found [8]. This was attributed to
non-specific oxidation of 25-OH-D3. However, we found that
incubation of l,25(OH)2D3 with PM for 16 hours resulted in
almost total conversion of this metabolite to 19-nor, lO-oxo,
25-OH-D3 (Fig. 7). Thus, it appears that the main metabolite
formed is l,25(OH)2D3, but this is largely oxidized following a
long incubation period to l9-nor,10-oxo-25-OH-D3. This fact
may be of clinical significance, since peritoneal fluid remains in
the abdomen of CAPD patients usually between six and eight
hours.
To further investigate the mechanism of the metabolism of
25-OH-D3 by PM, we looked at the possible role of humoral
factors in the peritoneal effluent. Incubation of control PM with
peritoneal effluent of CAPD free of peritonitis caused a marked
increase in metabolism of 25-OH-D3, whereas incubation with
fresh dialysis fluid had no effect. A further increase was found
when normal PM were incubated with peritoneal effluent from
patients with acute peritonitis. An obvious explanation of this
result could be the presence of uremic toxins present in the
dialysate of CAPD patients, which could stimulate the perito-
neal macrophages. However, since the PM of uremic patients
obtained from the dialysate of the initial peritoneal dialysis did
not metabolize 25-OH-D3, it seems that the uremic state per se
is not responsible for this phenomenon.
It is thus reasonable to assume that factors related to the
25(OH)D3
1500
Fig. 4. The amount of 1 ,25(OH)2Dçlike metabolite produced by mac-
rophages from CAPD patients, and macrophages from CAPD patients
treated with indomethacin. Results are expressed as mean s. The
number of subjects is given in parentheses.
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Fig. 5. Rechromatography of the J,25(OH)2D3-like peak on a Zorbax
Si! column and dichloromethane: methanol (97.5 :2.5) solvent. The
upper curve represents absorbance of the added standards. The bars
represent radioactivity of the metabolite produced from [3H] 25-OH-D3.
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Fig. 6. Rechromatography of the
1 ,25(OH)D3-like peak on reverse phase
HPLC (TSK ODS-120T, 5 s, 4.6 x 250 mm
column, LKB), using methanol:water (85:15)
as solvent. The upper curve represents
absorbance at OD 254 and 290 nm of the
added standards. The bars represent
radioactivity of the metabolite produced from
[3H1 25-OH-D3.
abdominal environment of CAPD patients may be implicated in
the generation of these humoral factors. Steinhauer, Gunter and
Schollmeyer found that detectable levels of prostaglandins are
present in the dialysate of CAPD patients [9], and a severalfold
increase in these levels occurs during peritonitis. Furthermore,
Yamada et al demonstrated that intrarenal administration of
PGE2 in rats enhanced 1 ,25(OH)2D3 production by the kidney
[10]. We thus incubated PM of control subjects with PGE2, and
found that this caused a marked stimulation of 25-OH-D3
metabolism. Moreover, incubation of PM of CAPD patients in
the presence of indomethacin results in a significant decrease in
25-OH-D3 metabolism. Thus these results indicate that pros-
taglandins are implicated in the synthesis of vitamin D metab-
olites by PM. However, other cytokines, such as gamma
interferon, which is known to be a potent in vitro stimulator of
the synthesis of vitamin D metabolites [1 lb may also be
involved.
Extrarenal metabolism of 25-OH-D3 was first demonstrated
in human bone cells in culture by Howard et al [31, and later in
alveolar macrophages of sarcoidosis patients [4]. Although the
main metabolite produced by macrophages in the latter condi-
tion was shown to be 1 ,25(OH)2D3 by Adams et al [4], Okabe et
al later identified this product as 19-nor, 10-oxo,25-OH-D3 [12].
The latter is known to be produced in vitro by human peripheral
blood monocytes and neutrophils, cultured kidney cells and HL
60 cells [13—15]. The mechanism by which 19-nor,10-oxo,
25-OH-D3 is produced is unclear. Tran and Henry, using short
incubation times, provided evidence for a nonenzymatic pro-
tein-dependent reaction [16]. Gardner et al [17], and Hayashi et
al [181, using 24 hour incubations, demonstrated 19-nor,10-oxo,
25-OH-D3 production even in the absence of proteins. Simi-
larly, Yamada, Takayama and Suda showed that it could be
produced simply by incubation of 25-OH-D3 in cell-free media
[19]. The metabolite 19-nor, lO-oxo, 25-OH-D3 competes with
l,25(OH)2D3 for its receptor, but with a much lower affinity
[20]. It thus shows biological activity, such as stimulation of
bone resorption in vitro, and stimulation of oxidative metabo-
lism of mononuclear phagocytes [14, 20]. The molecular struc-
ture of 19-nor, lO-oxo, 25-OH-D3 is quite similar to that of
1 ,25(OH)2D3. In the former metabolite, the 19-CH2 group has
19-nor-i 0-oxo-25(OH)D
C00)(N
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been replaced by oxygen. It is thus probable that the main
metabolite synthesized by PM is indeed 1 ,25(OH)2D3, but in a
further step, this metabolite is oxidized by the peroxide radicals
released by the PM themselves, or by factors present in the
medium, to form 19-nor,lO-oxo,25-OH-D3. We confirmed this
hypothesis by showing that 1 ,25(OH)2D3 incubated with PM of
CAPD patients was transformed almost totally to 19-nor,lO-
oxo, 25-OH-D3.
Does the peritoneal metabolism of 25-OH-D3 have any clin-
ical significance? Previous studies from our laboratory have
shown that in CAPD patients not receiving, calcitriol replace-
ment, plasma and peritoneal effluent levels of this metabolite
are undetectable [211. This suggests that the extrarenal produc-
tion of 1 ,25(OH)2D3 does not contribute to the plasma pool of
this metabolite in these patients. Dusso et al have shown the
existence of extrarenal production of 1 ,25(OH)2D3 in anephric
hemodialysis patients, but this was only after heavy oral dosage
with 25-OH-D3 [22]. It is possible that macrophage production
of 1 ,25(OH)2D3 could become clinically significant after oral
loading with 25-OH-D3. PM of CAPD patients have been shown
to have reduced antibacterial activity [23, 24], but, interest-
ingly, it has recently been shown that incubation of PM with
1 ,25(OH)2D3 greatly enhances their antibacterial activity [25,
26]. Thus, it is possible that in CAPD patients, l,25(OH)2D3
Fig. 7. Reverse-phase HPLC (TSK ODS-
120T, 5 , 4.6 x 250 mm column, LKB),
using methanol: water (85:15) as solvent,
following incubation of 106 PM with 200 pmol
[3jjj 1,25(OH)2D3. The upper curve represents
absorbance at OD 254 and 290 nm of the
added standards, and the bars represent
radioactivity of the metabolite produced from
3H1 1,25(OH)2D3.
produced by the PM themselves may contribute to the perito-
neal immune defenses.
Acknowledgments
The authors are grateful to Hoffman-La Roche, Basel, Switzerland
for providing the standards of vitamin D metabolites and Professor
Yamada, Tokyo University, Tokyo, Japan for providing the standard
19-nor, lO-oxo, 25-OH-D3 used in this study.
Reprint requests to Professor Shraga Shany, Toot Institute, Soroka
Medical Center, Beersheva 84101, Israel.
References
1. DELUCA HF: The kidney as an endocrine organ involved in the
function of vitamin D. Am J Med 58:39—47, 1975
2. Gax TK, LOWE W, LESTER GE: Vitamin D and pregnancy: The
maternal-fetal metabolism of vitamin D. Endocrinol Rev 2:26.4—274,
1981
3. HOWARD GA, TURNER RT, SHERRARD DJ, BAYLINK DJ: Human
bone cells in culture metabolize 25-hydroxyvitamin D3 to 1,25-
dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. J Biol Chem
256:7738—7740, 1981
4. ADAMS JS, SHARMA OP, GACAD MA, SINGER FR: Metabolism of
25-hydroxyvitamin D3 by cultured pulmonary alveolar macro-
phages in sarcoidosis. J Clin Invest 72:1856—1860, 1983
19-nor-10-oxo-25(OH)D
25(OH)D3
0
0
E0.
6000
4000
2000
0' fl
0 5 15
Time, minutes
20
Shany et a!: Metabolism of vitamin D by macrophages 1011
5. BARBOUR GL, Co8uIu' JW, SLATOPOLSKY E, NORMAN AW,
HORST RL: Hypercalcemia in an anephric patient with sarcoidosis:
Evidence for extrarenal generation of 1 ,25-dihydroxyvitamin D. N
Engi J Med 305:440—443, 1981
6. DELAFIELD JP, LEHRER RI: A simple microscopic method for
identifying and quantifying phagocytic in vitro. J immunol Meth
18:377—379, 1977
7. YAM LT, Li CT, CROSBY WH: Cytochemical identification of
monocytes and granulocytes. Am J Clin Patho! 55:283—290, 1971
8. HAYES ME, O'DONOGHUE DJ, BALLARDIE FW, MAWER EB:
Peritonitis induces the synthesis of la,25-dihydroxyvitamin D3 in
macrophages from CAPD patients. FEBS Lett 220:307—310, 1987
9. STEINHAUER HB, GUNTER B, SCHOLLMEYER P: Enhanced perito-
neal generation of vasoactive prostaglandins during peritonitis in
patients undergoing CAPD, in Frontiers in Peritoneal Dialysis,
edited by MAHER JF, WINCHESTER JF, New York, Field, Rich and
Assoc., 1986
10. YAMADA M, MAT5UMOTO T, TAKAHA5HI N, SUDA T, OGATA E:
Stimulatory effect of prostaglandin E2 on la,25-dihydroxyvitamin
D3 synthesis in rats. Biochem J 216:237—240, 1983
11. KOEFFLER H, REICHEL H, BIsHOP JE, NORMAN AE: Gamma-
Interferon stimulates production of I ,25-dihydroxyvitamin D3 by
normal human macrophages. Biochem Biophys Res Comm 127:
596—603, 1985
12. OICABE T, ISHIZUKA S, FUJISAWA M, WATANABE J, TAKAKU F:
Sarcoid granulomas metabolize 25-dihydroxyvitamin D3 in vitro.
Biochem Biophys Res Comm 123:822—830, 1984
13. LESTER GE, HOR5T RL, NAP0LI JL: Formation of 19-nor,10-keto-
25-hydroxyvitamin D3 in cultured mammalian cells. Biochem
Biophys Res Comm 120:919—925, 1984
14. Gi TK, MILLINGTON DS, MALTBY DA, WILLIAMS ME, COHEN
MS, DODD RC: Phagocytic cells synthesize 19-nor, l0-keto-25-
hydroxyvitamin D3, a metabolite that may induce differentiation of
the human monoblastic cell line U937. Proc Nat! Acad Sci USA
82:8218—8221, 1985
15. OKABE T, I5HIZUKA S, FUJISAWA M, WATANABE J, TAKAKU F:
Human myeloid cells metabolize 25-hydroxyvitamin D3 in vitro.
Biochem Biophys Res Comm 127:635—641, 1985
16. TRAN JM, HENRY HL: Characterization of 19-nor, 10-oxo-25-
hydroxyvitamin D3 production by solubilized chick kidney mito-
chondria and bovine serum albumin. J SteroidBiochem 33:395—403,
1989
17. GARDNER RM, ALLISON MJ, HARTMAN PA, REINHARDT TA,
HORST RL: Factors influencing production of 5(E)-19-nor-10-keto-
vitamin D3 by rumen bacteria. J Steroid Biochem 28:189-192, 1987
18. HAYASI-HT, YAMADA S, MIYAURA C, TANAKA H, YAMAMOTO K,
ABE E, TAKAYAMA H, SUDA T: Phagocytic cells metabolize 25-
hydroxyvitamin D3 to lO-oxo-l9-nor-vitamin D3 and a new metabolite,
8,25-dihydroxy-9, 10-seco-4,6, 10(19)-cholestatrien-3-one. FEBS Lett
218:200—204, 1987
19. YAMADA S. TAKAYAMA H, SUDA T: Metabolism of vitamin D in
phagocytic cells, in Vitamin D, Molecular, Cellular and Clinical
Endocrinology, edited by NORMAN AW, SCHAEFER K, GRIGOLEIT
HG, HERATH DV, New York, Walter de Gruyter Publishing Co.,
1988, pp. 102—111
20. Gi TK, KLECKNER NW, MALLOYPJ, FELDMAN D, SIVAM 0,
DODD RC, COHEN MS: Biological activity of 19-nor, 10-keto-25-
hydroxyvitamin D3. J Bone Miner Res 2:413—419, 1987
21. SHANY S, RAPOPORT J, GOLIGORSKY M, YANKOWITZ N, ZUILI I,
CHAIMOVITZ C: Losses of 1,25- and 24,25-dihydroxyvitamin D3 in
the peritoneal fluid of patients treated with continuous ambulatory
peritoneal dialysis. Nephron 36:111—113, 1984
22. Dusso A, LOPEZ-HILKER S, RAPP N, SLATOP'OLSKY E: Extrarenal
production of calcitriol in chronic renal failure. Kidney lAt 34:368—
375, 1988
23. KEANE WF, PETERSON PK: Host defence mechanisms of the
peritoneal cavity and continuous ambulatory peritoneal dialysis.
Pent Dial Bull 4:122—127, 1984
24. LAMPERI S. CAROZZI 5: Macrophage abnormlities in CAPD, in
Advances in Continuous Ambulatory Penitoneal Dialysis, edited by
KHANNA R, NOLPH KD, PROWANT B, TWARDOWSKI ZJ, ORE0-
POuLOS DG, Toronto, University of Toronto Press, 1986, pp. 99—101
25. CAROZZI S, NsmuMG, SCHELOTTO C, CAVIGLIA P, SANTONI 0,
BAROCCI S, VERSACEF, CANTALUPPI A, SALIT M, LAMPERI S:
Ca and I ,25(OH)2D3 enhance peritoneal macrophage (PMØ)
antimicrobial functions in CAPD, in Advances in Peritoneal Dial-
ysis, edited by KHANNA R, NOLPH KD, PROWANT B, TWARD-
OWSKI ZJ, OREoPouLos DO, vol 5, 1989, p. 103—1 10
26. LEVY R, KLEIN J, RUBINEK T, ALKAN M, SHANY 5, CHAIMOVITZ
C: Diversity in peritoneal macrophage response of CAPD patients
to 1,25-dihydroxyvitamin D3. Kidney mt 37:1310—1315, 1990
